2024 AUA preview: Dr. Elterman on key research in BPH
Dean S. Elterman, MD, MSc, FRCSC, highlights several studies in BPH being presented at the 2024 AUA Annual Meeting.
In this video, Dean S. Elterman, MD, MSc, FRCSC, highlights 4 studies in benign prostatic hyperplasia (BPH) that will be presented at the upcoming 2024 American Urological Association (AUA) Annual Meeting, which will take place on May 3 – 6 in San Antonio, Texas. Elterman is a urologist at the University of Toronto in Canada.
Elterman previewed the following abstracts:
- MP46-02 (Roehrborn et al): The Early Patient Experience Following Treatment with PUL and WVTT, Two Contemporary MISTs for BPH: Preliminary Results from the CLEAR Study
- MP06-15 (Elliott et al): The Optilume® Drug Coated Balloon for recurrent anterior urethral strictures: ROBUST III study 4-year interim results
- MP46-04 (Cerrato et al): Rezum for BPH: results from a large retrospective multicenter study
- MP27-01 (Gilling et al): 24-Month Outcomes from the ZEST Pilot studies of the Zenflow Spring System for the Treatment of Benign Prostatic Hyperplasia (BPH)
Blue light cystoscopy decreases risk of recurrence, progression in NMIBC
May 9th 2024“The results of the BRAVO study performed within the VA health care system showed significant decreases in the risk of recurrence and progression, as well as the potential for improved overall survival in patients who received a BLC compared to patients who received WLC only,” says Stephen B. Williams, MD, MBA, MS, FACS, FACHE.
